Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. [electronic resource]
Producer: 20050421Description: 1135-43 p. digitalISSN:- 0006-4971
- Amino Acid Sequence
- Animals
- Antigen-Presenting Cells -- immunology
- Antineoplastic Agents -- pharmacology
- Benzamides
- Bone Marrow Cells -- immunology
- CD4-Positive T-Lymphocytes -- immunology
- Dendritic Cells -- drug effects
- Imatinib Mesylate
- Immune Tolerance -- drug effects
- Lymphoma -- immunology
- Macrophages -- drug effects
- Mice
- Mice, Inbred BALB C
- Molecular Sequence Data
- Neoplasms -- drug therapy
- Ovalbumin -- chemistry
- Peptide Fragments -- chemistry
- Piperazines -- pharmacology
- Pyrimidines -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.